Teva Pharmaceutical Industries Ltd Insider Trading
Every director, officer and 10% holder of Teva Pharmaceutical Industries Ltd has to report each trade in its stock within two business days of making it. This is those filings.
TEVA on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Brian SavageInterim Chief Legal Officer2026-09-184.5K shat $38.69 | Sale | $174.2K |
| Brian SavageInterim Chief Legal Officer2026-09-182.5K shat $39.15 | Sale | $98.8K |
| Brian SavageInterim Chief Legal Officer2026-09-18314 shat $38.70 | Sale | $12.2K |
| Roberto MignoneDirector2026-09-18367.6K shat $39.06 | Sale | $14.4M |
| Amir WeissChief Accounting Officer2026-08-216.9K shat $37.61 | Sale | $261.2K |
| Amir WeissChief Accounting Officer2026-08-212.5K shat $37.63 | Sale | $94.1K |
| Ronit Satchi-FainaroDirector2026-08-21415 shat $37.25 | Sale | $15.5K |
| Evan LippmanEVP, Business Development2026-08-1718.6K shat $36.57 | Sale10b5-1 plan | $680.3K |
| Tal Zvi ZaksDirector2026-08-0517 shat $34.87 | Sale | $592.7 |
| Placid JoverSee "Remarks"2026-08-0312.8K shat $34.88 | Sale10b5-1 plan | $447.4K |
| Eric A HughesSee "Remarks"2026-08-0325.6K shat $34.88 | Sale10b5-1 plan | $892.1K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on TEVA
Follow Teva Pharmaceutical Industries Ltd (TEVA) by email
New trades in Teva Pharmaceutical Industries Ltd (TEVA) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.